Jasper Therapeutics

JSPRPhase 2

Redwood City, United StatesFounded 2018jaspertherapeutics.com

Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.

Market Cap

$34.4M

Founded

2018

Employees

11-50

Focus

Biotech

JSPR · Stock Price

USD 1.2333.77 (-96.49%)

Historical price data

AI Company Overview

Technology Platform

Targeted monoclonal antibody platform focused on depleting hematopoietic stem cells (HSCs) via the c-Kit (CD117) receptor to enable safer conditioning for stem cell transplant and gene therapy.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
Briquilimab	Urticaria Chronic	Phase 2
Briquilimab	Chronic Inducible Urticaria	Phase 1/2
Briquilimab	Chronic Spontaneous Urticaria	Phase 1/2
Humanized anti-CD117 Monoclonal Antibody (JSP191)	SCID	Phase 1/2
JSP191	Lower-risk Myelodysplastic Syndrome	Phase 1

Opportunities

Jasper's primary growth opportunity lies in establishing briquilimab as the preferred conditioning regimen for the expanding number of approved and investigational stem cell transplants and gene therapies.

Success in its lead indications could lead to label expansion into other rare genetic diseases and solid tumor settings requiring stem cell support.

The company is also positioned to develop next-generation c-Kit targeting assets.

Risk Factors

The company faces significant clinical trial failure risk, as its value is concentrated in a single asset.

It operates in a highly competitive space with alternative conditioning technologies emerging.

As a pre-revenue company, it remains dependent on capital markets for funding, exposing it to dilution risk and unfavorable financing environments.

Competitive Landscape

Jasper's main direct competitor is Magenta Therapeutics, which is developing an ADC also targeting c-Kit. The broader competitive set includes standard chemoradiation conditioning and emerging *in vivo* gene editing approaches that may bypass the need for conditioning. Jasper differentiates with its naked antibody's potential safety advantage and advanced clinical data in SCID.